Eos SENOLYTIX Presents Strong Preclinical Data for Lead Geropeptide PTC-2105, Boosting Merger Value

summarizeSummary

Eos SENOLYTIX, the company merging with Pulmatrix, announced compelling preclinical results for its lead candidate PTC-2105, showing significant improvements in body composition, physical function, and extended survival in aged mice. This data strengthens the rationale for the pending merger.

check_boxKey Events

• Positive Preclinical Data Presented

  Eos SENOLYTIX presented 'best-in-class' preclinical data for its lead geropeptide, PTC-2105, at the Sachs 2nd Annual Obesity & Cardiometabolic Innovation Forum.

• Improved Body Composition and Physical Function

  PTC-2105 demonstrated significant reductions in fat mass, gains in lean mass, and improved physical function in preclinical studies, without reduced food intake or rapid rebound weight gain.

• Extended Survival in Aged Mice

  The data showed multi-system improvements in healthspan, leading to significant increases in cancer-specific and overall survival in naturally aged mice, pushing survival past known lifespan limits.

• Differentiated Mechanism from GLP-1s

  PTC-2105 targets mitochondrial dysfunction and senescent cells, offering a unique approach compared to GLP-1 agonists by preventing lean mass loss and attenuated rebound weight gain.

auto_awesomeAnalysis

This filing provides critical positive news for Pulmatrix, which is in the process of merging with Eos SENOLYTIX and has previously issued a going concern warning. The strong preclinical data for Eos's lead asset, PTC-2105, particularly its ability to increase lean muscle mass, reduce fat, improve physical function, and extend survival in aged mice, significantly enhances the value proposition of the combined company. This development is crucial for the success of the merger and the future viability of Pulmatrix.